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A r t i c l e s of B-ALL cases remains to be defined. Previous reports identified a subset of B-ALL with a distinct gene expression profile 3 and frequent deletion of ERG, encoding the ETS-family transcription factor v-ets avian erythroblastosis virus E26 oncogene 4, 5 . ERG has a key role in hematopoietic differentiation [6] [7] [8] , megakaryopoiesis 9 and megakaryoblastic leukemia associated with Down syndrome [10] [11] [12] . ERG is frequently rearranged in carcinoma of the prostate 13 but rarely in acute leukemia 14 , and ERG overexpression is associated with poor outcome in acute myeloid leukemia 15 . ERG expression is temporally regulated during B lymphopoiesis (Supplementary Fig. 1 ), suggesting that ERG may regulate B-lymphoid development; however, its role in the pathogenesis of ALL is unknown.
RESULTS
A subtype of B-ALL with DUX4 rearrangement and ERG deletion
To understand the genetic basis of the previously identified subtype of B-ALL, we studied a cohort of 1,913 individuals with B-progenitor ALL, including 1,347 children, 395 adolescents (ages 16-20 years) and 171 young adults (ages 21-39 years) with B-progenitor ALL using gene expression profiling and analysis of DNA copy number alterations by SNP array in all cases together with whole-genome (n = 32), wholeexome (n = 44) and/or transcriptome (n = 54) sequencing in a subset of cases (Supplementary Tables 1 and 2) .
Microarray and transcriptome sequencing data identified 141 (7.6%) ALL cases with a distinct gene expression profile (Fig. 1a,b,  Supplementary Fig. 2 and Supplementary Table 3 ). This form of leukemia constituted 5.2% of childhood standard-risk, 9.4% of childhood high-risk, 10 .2% of adolescent and 5.4% of adult ALL cases.
Eighty-five (55.6%) of these cases had focal deletions of ERG on chromosome 21q22.3 (Fig. 1c,d ), which were not observed in other B-ALL or T-ALL cases. The ERG deletions were confirmed by genomic qPCR and breakpoint mapping; they most commonly involved exons 3-7 (n = 27) or 3-9 (n = 22) of ERG transcript variant 1 (NM_182918.3; the most abundantly expressed transcript in non-B ALL and normal B cells) 16 . The presence of conserved heptamer recombination signal sequences at deletion breakpoints and intervening non-consensus nucleotides indicated that the deletions arise from aberrant recombination-activating gene (RAG) activity (data not shown). Genomic analysis of a panel of leukemia cell lines showed that Each column corresponds to a case, and data are presented as log 2 copy number ratios; deletions are shown in blue. The position of the ERG locus is indicated by an arrow on the left, and genomic coordinates are given on the right. Cases are ordered from left to right according to the extent of the deletion, with focal exon 1 deletions on the left, the common exon 3-7 and 3-9 deletions in the middle, and whole-gene deletion on the right. (d) Representative DNA copy number data for four cases with ERG deletion. Plots show log 2 copy number ratios from probe-level data; deletions appear below the x axis. The extent of deletion in each case is indicated by the horizontal bar, with black bars representing heterozygous deletion and red bars representing homozygous deletion.
the B-progenitor cell line NALM-6 exhibited a similar gene expression profile and an intragenic ERG deletion (Supplementary Fig. 3) .
Notably, genes of the double-homeobox (DUX) gene family on chromosomes 4q and 10q were among the top upregulated genes ( Fig. 2a and Supplementary Table 3) . Analysis of transcriptome sequencing data showed that all cases sequenced exhibited rearrangement of DUX4 to IGH, placing DUX4 under the control of the immunoglobulin heavy chain enhancer and resulting in increased expression of DUX4 (Supplementary Table 2 ). DUX4, which encodes a double-homeobox transcription factor, is located in a macrosatellite repeat in the subtelomeric repeat unit of chromosome 4q (ref. 17) . Deletion of part of this repeat unit is causative of facioscapulohumeral dystrophy, and DUX4 rearrangements have been reported in a subset of Ewing-like sarcoma (CIC-DUX4) 18, 19 and, recently, in a subset of ALL 20 . In each case of this subtype, DUX4 was inserted adjacent to the IGH enhancer region ( Supplementary  Fig. 4a and Supplementary Note), resulting in variable truncation of the C terminus of DUX4 and appendage of a variable number of amino acids from read-through into the IGH locus ( Fig. 2b-d and Supplementary Note). IGH-DUX4 rearrangement was confirmed in all six cases selected for validation by RT-PCR and/or genomic PCR ( Supplementary Fig. 4b ,c and Supplementary Table 4), and DUX4 overexpression was confirmed by immunoblotting (Fig. 2d) . Thus, DUX4 rearrangement is a universal feature of this subtype of B-ALL with a distinct gene expression profile, and ERG deletion is identified in the majority of cases.
The genomic landscape of DUX4-rearranged B-ALL Analysis of genome, exome and transcriptome data demonstrated that, in addition to universal rearrangement of DUX4 and frequent deletion of ERG, this subtype of ALL is characterized by a distinct mutational landscape (Fig. 3) . We identified a mean of 17.5 non-silent sequence mutations per case (range 2-42) and a paucity of structural genetic alterations (Supplementary Tables 5-9 ). Alterations of lymphoid transcription factor genes were present in 46.5% of cases (IKZF1, 36.7% and PAX5, 11.3%). Notably, whereas IKZF1 alterations are associated with poor outcome in other subtypes of childhood B-ALL 21,22 , they were not associated with poor outcome in childhood DUX4/ERG ALL (Supplementary Fig. 5 ). Mutations in transcription factors and transcriptional regulators were observed in 21% of DUX4/ERG cases, including in MYC, MYCBP2, MGA and ZEB2, that were uncommon in other subtypes of B-ALL, including 209 representative B-ALL and 16 T-ALL cases subjected to whole-genome or whole-exome sequencing (a listing of recurrently mutated and deleted genes across ALL subtypes is provided in Supplementary Table 10 ). Additional recurrent mutations affected genes involved in activation of Ras signaling (35.2%), cell cycle regulation (22.5% of cases) and epigenetic modifiers (56.3%), most commonly KMT2D, SETD2, ARID2 and NCOR1 (Supplementary Fig. 6 ).
ERG deregulation in DUX4-rearranged B-ALL DUX4-rearranged cases also exhibited profound transcriptional deregulation of ERG. Although the absolute level of expression of ERG was not higher than that in other ALL subtypes, this subtype of ALL was characterized by expression of multiple aberrant coding and noncoding ERG isoforms. Using RT-PCR, we detected internally deleted ERG transcripts with deletions corresponding to exons 3-7 and 3-9 ( Supplementary Fig. 7a ). Translation of these internally deleted transcripts was predicted to result in frameshift and premature truncation. However, corresponding N-terminally truncated ERG proteins were not identified in immunoblotting of leukemic cells harboring ERG deletions (data not shown). In contrast, immunoblotting using antibodies specific to the C terminus of ERG identified a 28-kDa ERG protein in 50 (63.2%) of the 79 DUX4/ERG ALL cases tested, including cases lacking an ERG deletion, suggesting an alternate mechanism of ERG deregulation (Supplementary Fig. 7b ).
Of the 54 DUX4-rearranged cases subjected to transcriptome sequencing, the majority expressed aberrant ERG transcripts that initiated in intron 6 (Supplementary Table 11 ). The most abundantly expressed isoform was initiated from a novel exon whose 3′ splice site was located 197 nt upstream of exon 7 (exon 6 alternate, or exon 6 alt; Fig. 4a ). The genomic boundaries of this non-canonical exon were determined by RACE, RT-PCR with primer walking and analysis of the orientation of RNA-seq read pairs mapping to this region. These analyses confirmed splicing of exon 6 alt to exon 7 and downstream exons, without evidence for splicing of upstream exons into exon 6 alt, indicating that exon 6 alt is a non-canonical first exon (Supplementary Fig. 8 ).
RT-PCR demonstrated in-frame splicing from ERG exon 6 alt into exon 7, resulting in expression of an ERG protein with a new N terminus of seven amino acids encoded by exon 6 alt followed by exons 7 through 10 of ERG isoform 1 (ERGalt a; Fig. 4b ). The predicted size of this truncated C-terminal ERG protein corresponded to the size of the protein identified by immunoblotting of ERG ALL leukemic cells (Supplementary Fig. 7c) .
We next systematically analyzed expression of canonical and non-canonical ERG transcripts across a range of leukemias and solid tumors using data from the St. Jude Children's Research Hospital- 
A r t i c l e s
Washington University Pediatric Cancer Genome Project. In addition to ERGalt a, we identified a second isoform with coding potential also encoded using ERG exon 6 alt, ERGalt b, and two less abundant transcripts that lacked coding potential (ERGalt c and d; Fig. 4c and Supplementary Table 11 ). Expression of the coding isoforms, ERGalt a and b, was observed in the majority of ERG ALL cases and accounted for the majority of transcripts expressed in such cases, but was uncommon and occurred at a low level in non-ERG cases, such as a minority of BCR-ABL1 (Ph + ) ALL cases (Fig. 4d) . Analysis of other pediatric ALL cases (n = 290) and non-hematopoietic tumors (n = 572) showed that expression of non-canonical ERG transcripts was observed in a minority of other B-ALL cases (for example, Ph + ALL), but these transcripts usually lacked coding potential. In contrast, high-level expression of ERG transcripts initiated from exon 6 alt Figure 3 Structural and sequence alterations in DUX4/ERG ALL. The heat map shows genomic data for DUX4/ERG ALL cases, each of which is represented by a column; genes are grouped by functional pathway. The color for each type of genetic alteration is defined below. The genomic profiling performed and presence/absence of ERGalt, ALE and DUX4 rearrangement are shown at the top: yellow, assay performed or alteration present; white, assay not performed or alteration absent; black, data not available. WGS, whole-genome sequencing; RNA, RNA-seq analysis; WES, whole-exome sequencing.
was restricted to DUX4-rearranged cases, which was confirmed by quantitative RNA-seq and qRT-PCR (Supplementary Table 12 ). Additional evidence of ERG deregulation was observed, with intron retention upstream of ERG exon 7 ( Supplementary Fig. 9 ). Analysis of stranded total RNA-seq data from 12 DUX4/ERG B-ALL cases, 40 other B-ALL cases and normal B cell progenitors identified expression of a long noncoding RNA proximal to the first exon of ERG in the majority of DUX4/ERG cases that was restricted to this form of leukemia and was observed in cases with and without ERG deletion (we call this RNA antisense long noncoding RNA associated with ERG, or ALE; Supplementary Figs. 10 and 11, and Supplementary Tables 12 and 13).
DUX4 binds and induces deregulation of ERG
The finding of DUX4 rearrangement as a universal feature of this subtype of ALL together with the unique presence of ERG deregulation and deletion suggests that the two phenomena are related and may contribute to leukemogenesis. DUX4 is known to induce deregulated expression of many genes, including ones encoding transcripts using alternate exons 23 .
To examine the relationship between DUX4 expression and ERG deregulation, we first analyzed previously reported ChIP-seq data for DUX4 expressed in human myoblasts 23 . This analysis identified a peak of DUX4 binding at the first, non-canonical exon of ERGalt, with two DUX4 binding motifs within this 372-nt region ( Supplementary  Fig. 12a ). Moreover, analysis of RNA-seq data showed that expression of DUX4 in myoblasts resulted in expression of ERGalt transcript that was not observed in cells lacking expression of DUX4 ( Supplementary  Fig. 12a ). Using ChIP-PCR, we observed binding of DUX4 to the first exon of ERGalt in NALM-6 cells ( Supplementary Fig. 12b ). We next performed DUX4 ChIP-seq in NALM-6 and Reh (ETV6-RUNX1 ALL) cells that confirmed DUX4 binding at exon 6 alt of ERG (Fig. 5a) , as well as at additional transcripts deregulated in DUX4/ERG ALL (Supplementary Fig. 12c ). ATAC-seq demonstrated a peak of chromatin accessibility at ERG exon 6 alt in NALM-6 and xenografted DUX4/ERG leukemic cells, but not in the Reh cell line ( Fig. 5a and Supplementary Fig. 13 ). A comprehensive listing of all peaks of DUX4 binding identified by ChIP-seq annotated with DUX4/ERG gene expression and ATAC-seq data is provided in Supplementary Table 14 .
We systematically analyzed the expression of transcripts using noncanonical first exons in stranded total RNA-seq data and identified 45 transcripts that were deregulated in DUX4/ERG ALL, of which 3 (ERG, NSD1 and RNGTT) were bound by DUX4 (Supplementary Table 15 ). ERGalt was the second most frequently deregulated transcript using a non-canonical first exon and was the most frequently deregulated of the loci bound by DUX4.
To examine the role of DUX4 overexpression in the deregulation of ERG, we transduced human cord blood hematopoietic cells and the ETV6-RUNX1 B-ALL cell line Reh with lentiviral vectors expressing DUX4 alleles corresponding to those identified in patients (DUX4 Glu415* and Gln334*) or empty lentiviral vector as a control. Truncated DUX4 induced expression of ERGalt in both Reh and human CD34 + cord blood cells, as shown by both transcript and protein analysis (expression of full-length DUX4 was not tolerated in the HEK293T vector producer cells) (Fig. 5b,c and Supplementary Fig. 12d ).
Together, these findings suggest that ERG deregulation is caused by overexpression of DUX4, which binds to the alternative transcription initiation site in ERG intron 6, and that ERG deletion is a secondary event occurring in a transcriptionally active locus primed for RAG-mediated deletion. Such deletion of ERG may further impair A r t i c l e s expression of wild-type ERG. Consistent with this proposed mechanism and sequence of deregulation, transcription of ERGalt is initiated in ERG intron 6, which lies within the regions commonly deleted in ERG (exons 3-7 and 3-9). Thus, in contrast to other key targets of deletion in ALL such as PAX5 and IKZF1, the deleted ERG allele cannot encode the putative oncogenic isoform, but rather this isoform is encoded by the non-deleted ERG allele. In addition, some DUX4/ERG cases expressing ERGalt lacked a clonal ERG deletion but had evidence of subclonal deletions. Of the 54 cases with transcriptome data, 46 expressed ERGalt and 27 of these had a clonal ERG deletion. However, seven cases lacking such a deletion had evidence of a subclonal deletion in genomic PCR analysis (Supplementary Table 2) , and emergence of clonal ERG deletions was observed in mice with xenografts of cells from human cases and in cases of relapsed ALL in which the characteristic gene expression profile was present at both diagnosis and relapse, but in which clonal ERG deletions were only observed at relapse (data not shown). Together, these data support the notion that ERG deletions are secondary genomic events but, if acquired sufficiently early in leukemogenesis, may be present as clonal events.
ERGalt inhibits ERG activity and promotes leukemogenesis
ERGalt lacks the N-terminal pointed domain and central regulatory domains of wild-type ERG but retains the DNA-binding ETS and transactivation domains. Both wild-type ERG and ERGalt exhibited nuclear localization and bound DNA target sequences ( Supplementary Fig. 14a and data not shown). In a transcriptional reporter assay using an ERG target gene, gpIX (GP9) 24 , ERGalt displayed diminished transactivation ability and acted as a competitive inhibitor of wild-type ERG (Supplementary Fig. 14b,c) .
These results suggest that ERGalt may directly contribute to leukemogenesis, in part by inhibiting the function of wild-type ERG. To explore this possibility, lineage-negative (Lin − ) bone marrow from mice homozygous for a Cdkn2a knockout allele that results in loss of expression of the p19 ARF tumor suppressor (Arf −/− ) was transduced with supernatants containing retroviruses expressing wild-type ERG or ERGalt and/or an activated NRAS allele and/or IK6, the dominant-negative form of IKZF1 commonly observed in human ALL, followed by in vitro culture and transplantation of transduced cells into lethally irradiated recipient mice. Expression of human (ERGalt) and NRAS Gly12Asp together promoted serial replating of lymphoid cells (Supplementary Fig. 15 ). Consistent with previous reports, expression of wild-type ERG induced lethal erythromegakaryoblastic leukemia (Fig. 6a-d) 25 . In contrast, mice transplanted with ERGaltexpressing cells developed lymphoid precursor, biphenotypic or pre-B cell leukemia with longer latency (Fig. 6a-d) , indicating that ERGalt directly promotes lymphoid leukemogenesis. [26] [27] [28] [29] .
DISCUSSION
The striking deregulation and deletion of ERG is unique to this subtype of ALL. Although multiple previous studies have reported ERG deletions in B-ALL 5, 22, 30, 31 , including in DUX4-rearranged cases 32 , several of these studies identified only cases harboring the common deletions and used these as a surrogate to identify a subset of ALL cases with favorable prognosis 30, 31 . In contrast, we show that ERG transcriptional deregulation is a hallmark of this subtype, with diverse ERG deletions in a majority of but not all cases. Multiple mechanisms of ERG genomic alteration were observed. These included expression of aberrant ERG transcripts in all cases, including non-canonical coding transcripts, intron retention and expression of a long noncoding RNA, with expression of the novel coding ERG transcript ERGalt present in the majority of cases; clonal or subclonal ERG deletions were also observed in the majority of cases. We have shown that DUX4 directly binds to the ERG locus at the first, non-canonical exon of ERGalt and, in multiple hematopoietic and non-hematopoietic cell types, directly induces expression of ERGalt. The deregulation of ERG by DUX4 is reminiscent of deregulation of other ETS-family genes in solid tumors 19 and represents a new mechanism of ETS gene deregulation in leukemia. Moreover, as ERG may represent one of potentially many genes deregulated by DUX4, we performed a systematic, genomewide integrated analysis including gene expression analysis, analysis of the expression of genes using non-canonical first exons, DUX4 ChIP-seq and ATAC-seq and show that ERGalt is the top deregulated transcript in this form of leukemia for which DNA is bound by DUX4 and uses a non-canonical first exon.
The observations that ERG is deleted in only a subset of cases and that expression of ERGalt is directly induced by DUX4 suggests that ERG deregulation is an important but secondary event in leukemogenesis. In addition, we have shown that, for the majority of cases harboring an ERG deletion, deregulation of the ERG locus involves both alleles and cannot be explained by perturbation of a single copy of the gene. The common ERG deletions remove intron 6, which harbors ERG exon 6 alt, the first exon encoded in ERGalt, and the region bound by DUX4. Thus, in a case with a clonal ERG deletion, ERGalt must be expressed from the non-deleted ERG allele. Our data therefore suggest a sequence of events in which rearrangement of DUX4 is an early, leukemia-initiating event that results in binding of DUX4 to 
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the ERG locus and deregulated expression of coding and noncoding transcripts. The resulting increased chromatin accessibility evidenced by ATAC-seq renders the locus susceptible to RAG-mediated deletion of ERG. Should this occur early in leukemogenesis, ERG deletion is observed as a clonal event, but if it occurs later it manifests as a subclonal event that may become clonal during disease progression (for example, at relapse or, as a surrogate, through passage in an immunocompromised mouse). The interplay between DUX4 and ERG deregulation in leukemogenesis will require detailed future examination in appropriately engineered mouse models that must account for the fact that ERG exon 6 alt is incompletely conserved in the mouse; primary mouse hematopoietic cells were thus not suited to examining induction of ERGalt by DUX4. That notwithstanding, the findings of inhibition of the transcriptional activity of wild-type ERG by ERGalt and documentation of aberrant intron retention and/or deletion of ERG in all cases in this form of leukemia, but rarely in any other tumors, indicate that inhibition or loss of ERG activity is required in the pathogenesis of human DUX4/ERG ALL. The notion that ERGalt sustains lymphoid colony replating and induces leukemia with longer latency than wild-type ERG, but with a shift to a biphenotypic or lymphoid lineage, further supports this view.
These findings have important clinical implications, as DUX4/ERG ALL is associated with favorable outcome, irrespective of the presence of concomitant genetic alterations otherwise associated with poor outcome in other contexts, such as deletion of IKZF1. DUX4 rearrangement is not evident in karyotypic analysis and is challenging to identify in analysis of genome sequencing and RNA-seq data because of the repetitive nature of both breakpoints and the nature of DUX4 insertion into the IGH locus. Thus, in contrast to previous studies that have used identification of only the common (and clonal) ERG deletions as a surrogate for the identification of a distinct type of leukemia 30, 31 , future studies must move beyond identification of ERG deletions alone to identify this form of leukemia. All cases harbor rearrangement of DUX4, the detection of which requires transcriptome and/or genome sequencing. Quantification of DUX4 expression may also identify cases with rearrangements but must be performed carefully in view of the highly paralogous nature of the DUX family of genes. Conventional cytogenetic approaches such as FISH are challenging because of the repetitive nature of the DUX4 locus. Identification of such cases, however, is important to accurately assign risk and guide therapy.
URLs. The genomic landscape can be explored at the St. Jude PeCan Data Portal available at http://pecan.stjude.org/proteinpaint/ study-mullighan_dux4_erg. Data may be accessed at https://pecan. stjude.org/permalink/erg/. Data derived from COG samples may also be accessed through the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) website at https://ocg. cancer.gov/programs/target. Covaris truChIP protocol, http:// covarisinc.com/wp-content/uploads/pn_010179.pdf.
METHODS
Methods and any associated references are available in the online version of the paper.
Accession codes. Genome, exome and RNA-seq data have been deposited at the European Genome-phenome Archive (EGA) under accessions EGAS00001000514, EGAS00001000654, and EGAS00001001923. Microarray gene expression and SNP microarray data have been deposited in the database of Genotypes and Phenotypes (dbGaP) under accession phs000463.v12.p5. 
ONLINE METHODS
Patients and samples. Diagnosis and remission samples were obtained from St. Jude Children's Research Hospital, the Children's Oncology Group, the Alliance-Cancer and Leukemia Group B, the Eastern Cooperative Oncology Group and the MD Anderson Cancer Center. We examined leukemia samples obtained at diagnosis from 1,913 children (up to 16 years of age), adolescents (16-21 years) and young adults (21-39 years) with B-progenitor ALL (Supplementary Table 1 ) using microarray gene expression profiling and SNP array analysis. The study was approved by the St. Jude Institutional Review Board, and informed consent was obtained from patients or legal guardians.
Genomic analysis. Whole-genome, whole-exome and transcriptome sequencing and gene expression and SNP array analysis were performed as previously described 33 , . Additional details of bioinformatic analysis are provided in the Supplementary Note. The genomic landscape was summarized using ProteinPaint 34 .
Whole-genome and/or whole-exome sequencing was performed for ERG-altered B-ALL cases (n = 72 cases), ETV6-RUNX1 ALL cases (54), ALL cases with high hyperdiploidy (39), BCR-ABL1 ALL cases (39), ALL cases with low hypodiploidy or nearly haploid karyotypes (n = 19), TCF3-PBX1 ALL cases (17) , BCR-ABL1-like ALL cases (17) , miscellaneous B-ALL cases (17), T-lineage ALL cases (17) and B-ALL cases with rearrangement of CRLF2 (7). Paired-end whole-genome sequencing of tumor and normal DNA samples was performed using HiSeq 2000 genome sequencers (Illumina) as previously described to at least 30-fold haploid coverage. Exome sequencing was performed using TruSeq exome capture baits (Illumina) and GAIIx or HiSeq 2000 sequencers as previously described 35 . Sequence mapping and variant calling were performed as described 35, 36 . Data were visualized in ProteinPaint 34 .
Transcriptome sequencing was performed for 175 B-ALL cases, including ERG-altered cases (54 cases), ETV6-RUNX1 cases (54), BCR-ABL1-positive and BCR-ABL1-like ALL cases (27 each), hypodiploid ALL cases (8) , and high-hyperdiploid and miscellaneous ALL cases (5). Total RNA was extracted from leukemia cells using TRIzol (Life Technologies). Total RNA quality and quantity were assessed on Agilent RNA6000 chips (Agilent Technologies) and Qubit (Life Technologies). RNA-seq libraries were prepared from 1 µg of total RNA for each sample following Illumina RNA-seq protocols, including DNase treatment and phenol purification, poly(A) + RNA selection with oligo(dT) beads, cDNA conversion, fragmentation by Covaris Ultrasonicator, end repair, deoxyadenosine tailing, adaptor ligation and PCR amplification (ten cycles). Libraries with a 10 pM concentration were clustered on an Illumina cBot, and each flow cell was loaded onto a HiSeq instrument for sequencing using the Illumina 2 × 100 bp sequencing kit.
Transcriptome sequencing data were mapped to the human genome (hg19) using in-house software, and the resulting alignments were analyzed to identify evidence of both known and new splicing events. Predicted splice junction sites were post-processed with a software package called RNApeg to correct mapping ambiguities and apply minimum quality control requirements to new junction calls. RNApeg evaluates junctions for microhomologous mapping ambiguity in comparison to reference junctions in the refGene, Ensembl, AceView and UCSC known gene databases, also correcting against new exon skips and single-edge matches in those isoforms. Novel junctions without any available reference anchoring are compared with each other and across samples, facilitating standardized comparison. Where ambiguity was identified, coordinates are adjusted and supporting read evidence is combined, producing a more compact and consistent set of junction calls.
The transcript expression levels in transcriptome sequencing data were estimated as FPKM values. Briefly, read counts in the corresponding GENCODE annotated gene model were obtained with the HTseq-count program 37 . FPKM values were computed by normalizing the obtained read counts for a transcript or gene with the length of the transcript or gene and the total mapped reads.
A gene was called 'expressed' in a given sample if it had FPKM ≥0.35 based on the distribution of FPKM gene expression levels, and we filtered out genes that were not expressed in any sample from the final gene expression data matrix for downstream analysis. Similar to expression arrays, limma 38 with estimation of the false discovery rate (FDR) 39 was also performed to compare ERG and other B-ALL samples (FDR < 0.05).
Stranded total RNA-seq was performed for 6 B-lymphoid progenitor samples flow sorted from human bone marrow, 12 ERG ALL cases and 40 non-ERG B-ALL cases. The expression levels of ERGalt and ALE were examined in 922 hematopoietic, brain and solid tumor cases sequenced by the St. Jude-Washington University Pediatric Cancer Genome Project and in adult tumor cases sequenced by The Cancer Genome Atlas (non-smallcell adenocarcinoma, n = 308; squamous non-small-cell lung cancer, n = 279; low-grade glioma, n = 467; glioblastoma multiforme (GBM), n = 167; ovarian cancer, n = 15).
ATAC-seq. ATAC-seq was performed using cell lines (NALM-6 and Reh) and xenografts of DUX4/ERG ALL as previously described with minor modifications 40 . NALM-6 and Reh cells were obtained from the Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures and were subjected to SNP array and transcriptome sequencing; they were tested for Mycoplasma contamination before use. Briefly, 50,000 cells were lysed and isolated nuclei were resuspended in 2× TD buffer. Transposase reactions were purified using MinElute columns (Qiagen), and library fragments were amplified using NEB Next HiFi 2× MM (New England BioLabs), with qPCR cycle optimization performed using Kapa SybrFast 2× MM (Kapa Biosystems). The products from amplification were purified using two rounds of incubation with Agencourt AMPure XP SPRI beads at a 1.4× ratio (Beckman Coulter). Libraries were quantified via Qubit HS DNA kit (Life Technologies) and evaluated for library size distribution on a Bioanalyzer 2100 (Agilent Technologies). Sequencing was performed on a HiSeq 2000, generating paired 100-nt reads.
Reads were aligned to hg19 with BWA using default parameters after trimming Illumina adaptor sequences. Observed fragment sizes showed similar enrichment of nucleosome-free, mononucleosome, dinucleosome and trinucleosome fragments as described 40 . Reads were adjusted by transposon insertion offset, and unique aligned nucleosome-free fragments of less than 100 nt in size were extracted. Wig files were generated by extending these nucleosome-free fragments to 80 bp from the center and uploaded to the UCSC Genome Browser for visualization. Establishment of DUX4/ERG xenografts. Eight xenografts of human DUX4/ ERG ALL were established using NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NOD-SCIDγ-null, or NSG) mice 42 . Primary leukemia cells were intravenously injected into three to five 8-to 12-week-old female NSG mice per tumor, and engraftment was monitored by flow cytometry analysis of peripheral blood using antibodies against human CD19 and CD45. Engraftment was monitored by retro-orbital bleeding 4 weeks after injection and then every 2-4 weeks as necessary. Xenograft cells were isolated when the level of peripheral blood engraftment exceeded 50%. The work was approved by the St. Jude Institutional Animal Care and Use Committee. were thawed by the dropwise addition of X-VIVO 10 (Lonza), 50% HyClone Cosmic Calf Serum and 100 µg/ml DNase (Roche) and were cultured at a cell density of 1.6-2.5 × 10 6 /ml in X-VIVO 10 medium supplemented with 1% BSA (Roche), l-glutamine (Gibco), penicillin-streptomycin (Gibco) and the following cytokines (all from Miltenyi): SCF (100 ng/ml), Flt3L (100 ng/ml), TPO (50 ng/ml) and IL-7 (10 ng/ml).
For lentiviral overexpression studies, a pRRL-based and Gateway (Thermo Fisher)-adapted lentiviral vector was used in which transgene expression is driven by the SFFV promoter and tagBFP expression is driven by a chimeric EF1α/SV40 promoter (J.E.D., K.B.K., S.T. and E. Wienholds, unpublished data). The cDNA for wild-type and truncated DUX4 was PCR amplified from leukemic cell RNA and inserted into the vector via Gateway LR clonase reaction according to the manufacturer's instructions (Thermo Fisher). VSV-G pseudotyped lentiviral vector particles were produced by polyethyleneimine (PEI)-based cotransfection of 10.5 µg of pMD.G2, 20.5 µg of pCMVR8.74 (both from Addgene) and 38 µg of transfer vector into HEK293T cells 43 ChIP assays. ChIP assays were carried out as described previously 44 . Chromatin shearing was performed according to the truChIP shearing protocol (Covaris; see URLs) with minor modification. Briefly, 25 × 10 6 Reh and NALM-6 cells were incubated for 10 min in 1% formaldehyde in PBS at room temperature, quenched by the addition of 1/10 volume of 2.5 M glycine. Cells were then washed three times with cold PBS containing proteinase inhibitors and lysed on ice for 10 min in lysis buffer (50 mM HEPES, pH 7.9, 140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% NP-40, 0.25% Triton X-100). Chromatin was washed twice in washing buffer (10 mM Tris-HCl, pH 8, 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA) and then twice in shearing buffer (0.1% SDS, 10 mM Tris-HCl, pH 8, 1 mM EDTA) before resuspension in 1 ml of shearing buffer. Chromatin was sonicated in 1-ml AFA millitubes using a Covaris E210 instrument for 20 min at 5% duty cycle, intensity 4, 200 cycles per burst at 7 °C. Sheared chromatin was spun down for 10 min at 16,200g at 4 °C, and the supernatant was mixed with an equal amount of ChIP dilution buffer (0.1% SDS, 30 mM Tris-HCl, pH 8, 1 mM EDTA, 300 mM NaCl) before ChIP experiments. Immunoprecipitation was performed with an antibody to DUX4 (ab124699, Abcam) and a normal rabbit IgG control (Santa Cruz Biotechnology) using 2 µg of antibody per ChIP.
Real-time PCR (∆C t method) was employed to determine the enrichment of the human ERG locus among regions precipitated by antibody to DUX4. Signals were normalized to input as a percentile. The primer sequences used are given in Supplementary Table 16 .
To prepare ChIP-seq libraries, 10 ng of ChIP DNA was end repaired and adaptor ligation was performed using the NEBNext ChIP-Seq Library Prep Reagent Set for Illumina (New England BioLabs). Libraries were purified after 14 rounds of PCR amplification with Q5 DNA Hot-Start polymerase (New England BioLabs). Each ChIP-seq library underwent 50-cycle single-end sequencing using TruSeq SBS kit v3 on an Illumina HiSeq 2000.
Sequence reads were aligned to human genome hg19 (GRCh37) by BWA 45 (version 0.5.9-r26-dev; default parameters). Duplicate reads were marked with Picard (version 1.65(1160)), and only non-duplicate reads were retained for analysis (using SAMtools 46 (parameter "-q 1 -F 1024"; version 0.1.18 (r982:295)). Cross-correlation plots were generated by a non-duplicated version of SPP 47 (version 1.11) for quality control, and fragment sizes were estimated using caTools (version 1.17) and bitops (version 1.0-6) implemented in R (version 2.14.0). The best fragment size estimates from the cross-correlation plot were used to extend each read to generate bigwig files for viewing in the Integrative Genomics Viewer 48 (version 2.3.40), with scaling of the height of bigwig tracks by normalization to 15 million non-duplicate reads. All results from quality control analysis and visualization indicated that our data passed ENCODE criteria except for DUX4 ChIP-seq in Reh cells, where the results were similar to input DNA used as a control (relative strand correlation <1), which was expected because of the lack of DUX4 expression in this cell line. For annotation, MACS2 was used for peak calling (again using input DNA as a control) and only peaks overlapping in the two replicates for NALM-6 cells were retained and merged as finalized peaks. MAST 49 in the MEME suite 50 (version 4.10.2) was used to scan for DUX4 motifs (JASPAR 51 accession MA0468.1) within finalized NALM-6 DUX4 ChIP-seq peaks.
FISH. FISH for disruption of the ERG locus was performed for ten new B-ALL cases in the training cohort using diagnostic bone marrow or peripheral blood leukemic cells in Carnoy's fixative as previously described 5 . BAC clones RP11-50G3 (5′ of ERG) and RP11-720N21 (3′ of ERG) were labeled with rhodamine and fluorescein isothiocyanate, respectively. At least 100 interphase nuclei were scored per case.
RT-PCR and cloning. Wild-type ERG, ERGalt and ALE sequences were amplified using Advantage 2 DNA polymerase (Clontech). PCR primers are listed in Supplementary Table 16 . PCR products were purified, sequenced directly and after cloning into pGEM-T Easy (Promega), and subcloned into MSCV-IRES-GFP retroviral vectors.
Luciferase assays. Twenty-four hours after 20,000 HEK293T cells were plated per well of a 96-well plate, cells were transfected with equimolar amounts of vector encoding wild-type (MIG-ERG isotype 1) or mutant (MIG-ERG-e6alt) ERG or with MIG empty vector along with 250 ng of pGL3-gpIX luciferase reporter plasmid and 50 ng of pRL-TK Renilla luciferase plasmid DNA (Promega) using FuGENE 6 transfection reagent (Roche Diagnostics). Competition assays were performed by transfecting cells with increasing amounts of plasmid for mutant ERG together with a fixed amount of plasmid for wild-type ERG, or vice versa, with total plasmid amounts equalized with empty vector. Forty-eight hours after transfection, cell lysis and measurement of firefly and Renilla luciferase activity were performed using the Dual-Glo Luciferase Assay System (Promega) according to the manufacturer's instructions. Transfections were performed in triplicate in at least two independent experiments. Firefly luciferase/Renilla luciferase ratios are reported as means ± s.e.m.
Immunofluorescence and immunoblotting.
Cytospins of pre-B cells were fixed with 4% paraformaldehyde and washed with PBS, followed by incubation for 30 min in a blocking/permeabilization solution consisting of 10% normal goat serum and 0.1% Triton X-100 in PBS. Cells were then incubated for 1 h with primary antibody to ERG (Abcam, EPR3864) diluted 1:500 in 3% normal goat serum and 0.1% Triton X-100 in PBS. Slides were washed three times in PBS and then incubated for 45 min in 3% normal goat serum and 0.1% Triton X-100 in PBS containing a secondary antibody conjugated to Alexa Fluor 555 (Invitrogen). Slides were washed three times in PBS and mounted with Vectashield (Vector Labs) containing 4′-6-diamidino-2-phenylindol (DAPI). All steps were carried out at room temperature. Images were captured using a Nikon C2 confocal fluorescence microscope.
Immunoblotting of cell line and leukemic cell whole-cell lysates was performed as previously described 52 using antibodies specific to the N terminus of ERG (H-95, Santa Cruz Biotechnology), the C terminus of ERG (C-20, Santa Cruz Biotechnology) and a rabbit monoclonal antibody specific to the C terminus (Abcam, 133264). DUX4 immunoblotting was performed with antibodies specific to the C terminus (E5-5, ab124699, Abcam) and N terminus (aa82-131, LS-C205474, Lifespan Biosciences). All antibodies were used at a 1:1,000 dilution.
Gene transduction and transplantation of lineage-negative bone marrow cells. Mice were housed in an American Association of Laboratory Animal Care (AALAC)-accredited facility and were treated on Institutional Animal Care and Use Committee (IACUC)-approved protocols in accordance with US National Institutes of Health guidelines. For in vivo Lin − cell transplantation experiments, bone marrow from 8-week-old Arf −/− mice 53 was extracted from tibiae and femora. Red blood cells were lysed, and the remaining bone marrow cells were incubated with a cocktail of biotinylated antibodies to mouse proteins (Gr-1, B220, Ly-1, Ter119 and Mac-1; BD Biosciences) followed by mixing with streptavidin-coated beads (Dynabeads M-280 Streptavidin, Dynal 112.16, Life Technologies). Cells were separated on a magnet, and unbound cells were collected and incubated at 37 °C and 5% CO 2 for 2 d in the presence of IL-3, IL-6, SCF, IL-7 and Flt3 cytokines (Peprotech). Cells were retrovirally transduced with MIG-ERG WT or MIG-ERGalt on RetroNectin (Takara Bio) for 48 h before sorting for GFP + cells (BD FACSAria, BD Biosciences). Recipient 10-week-old female wild-type C57BL/6 mice were lethally irradiated (11 Gy) 24 h before transplantation with 200,000 GFP + cells via tail vein injection with 5-7 mice per experimental group. Animals were not randomized before transplantation. Animals were monitored, without blinding of investigators to experimental group, for the development of leukemia clinically by measurement of GFP expression in peripheral blood and were sacrificed when
